A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome
Identifieur interne : 000137 ( Istex/Corpus ); précédent : 000136; suivant : 000138A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome
Auteurs : Andrew D. Krahn ; George J. Klein ; Raymond YeeSource :
- Pacing and Clinical Electrophysiology [ 0147-8389 ] ; 2001-08.
English descriptors
- KwdEn :
Abstract
KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.
Url:
DOI: 10.1046/j.1460-9592.2001.01258.x
Links to Exploration step
ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title><author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name><affiliation><mods:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name><affiliation><mods:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name><affiliation><mods:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1046/j.1460-9592.2001.01258.x</idno><idno type="url">https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000137</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000137</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title><author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name><affiliation><mods:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name><affiliation><mods:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name><affiliation><mods:affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Pacing and Clinical Electrophysiology</title><idno type="ISSN">0147-8389</idno><idno type="eISSN">1540-8159</idno><imprint><publisher>Blackwell Futura Publishing, Inc.</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2001-08">2001-08</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1258">1258</biblScope><biblScope unit="page" to="1260">1260</biblScope></imprint><idno type="ISSN">0147-8389</idno></series><idno type="istex">118ADF7F2B55924522341A65CD078ED7E7AA300A</idno><idno type="DOI">10.1046/j.1460-9592.2001.01258.x</idno><idno type="ArticleID">PACE1258</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0147-8389</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>atrial fibrillation</term><term>dofetilide</term><term>supraventricular tachycardia</term><term>wolff‐parkinson‐white syndrome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>ANDREW D. KRAHN</name><affiliations><json:string>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item><json:item><name>GEORGE J. KLEIN</name><affiliations><json:string>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item><json:item><name>RAYMOND YEE</name><affiliations><json:string>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dofetilide</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>supraventricular tachycardia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>atrial fibrillation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>wolff‐parkinson‐white syndrome</value></json:item></subject><articleId><json:string>PACE1258</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</abstract><qualityIndicators><score>4.529</score><pdfVersion>1.2</pdfVersion><pdfPageSize>536.598 x 760.819 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractCharCount>1401</abstractCharCount><pdfWordCount>2189</pdfWordCount><pdfCharCount>13805</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>195</abstractWordCount></qualityIndicators><title>A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title><genre><json:string>article</json:string></genre><host><title>Pacing and Clinical Electrophysiology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1540-8159</json:string></doi><issn><json:string>0147-8389</json:string></issn><eissn><json:string>1540-8159</json:string></eissn><publisherId><json:string>PACE</json:string></publisherId><volume>24</volume><issue>8</issue><pages><first>1258</first><last>1260</last><total>3</total></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>engineering, biomedical</json:string><json:string>cardiac & cardiovascular systems</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>cardiovascular system & hematology</json:string></scienceMetrix></categories><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1046/j.1460-9592.2001.01258.x</json:string></doi><id>118ADF7F2B55924522341A65CD078ED7E7AA300A</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Futura Publishing, Inc.</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>© Futura Publishing Company, Inc. 2001</p></availability><date>2001</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title><author xml:id="author-1"><persName><forename type="first">ANDREW D.</forename><surname>KRAHN</surname></persName><affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</affiliation></author><author xml:id="author-2"><persName><forename type="first">GEORGE J.</forename><surname>KLEIN</surname></persName><affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</affiliation></author><author xml:id="author-3"><persName><forename type="first">RAYMOND</forename><surname>YEE</surname></persName><affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</affiliation></author></analytic><monogr><title level="j">Pacing and Clinical Electrophysiology</title><idno type="pISSN">0147-8389</idno><idno type="eISSN">1540-8159</idno><idno type="DOI">10.1111/(ISSN)1540-8159</idno><imprint><publisher>Blackwell Futura Publishing, Inc.</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2001-08"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1258">1258</biblScope><biblScope unit="page" to="1260">1260</biblScope></imprint></monogr><idno type="istex">118ADF7F2B55924522341A65CD078ED7E7AA300A</idno><idno type="DOI">10.1046/j.1460-9592.2001.01258.x</idno><idno type="ArticleID">PACE1258</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>dofetilide</term></item><item><term>supraventricular tachycardia</term></item><item><term>atrial fibrillation</term></item><item><term>wolff‐parkinson‐white syndrome</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-08">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-12-13">References added</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-02-8">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley component found"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Futura Publishing, Inc.</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1540-8159</doi><issn type="print">0147-8389</issn><issn type="electronic">1540-8159</issn><idGroup><id type="product" value="PACE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="PACING CLINICAL ELECTROPHYSIOLOGY">Pacing and Clinical Electrophysiology</title></titleGroup></publicationMeta><publicationMeta level="part" position="08008"><doi origin="wiley">10.1111/pace.2001.24.issue-8</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue" number="8">8</numbering></numberingGroup><coverDate startDate="2001-08">August 2001</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0125800" status="forIssue"><doi origin="wiley">10.1046/j.1460-9592.2001.01258.x</doi><idGroup><id type="unit" value="PACE1258"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><copyright>© Futura Publishing Company, Inc. 2001</copyright><eventGroup><event type="firstOnline" date="2003-07-22"></event><event type="publishedOnlineFinalForm" date="2003-07-22"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:Header result:Header" date="2010-03-02"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-06"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-03"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="1258">1258</numbering><numbering type="pageLast" number="1260">1260</numbering></numberingGroup><correspondenceTo>Address for reprints: Andrew Krahn, M.D., London Health Sciences Center, University Campus, 339 Windermere Rd., London ON Canada N6A 5A5. Fax: (519) 434‐3278; e‐mail: <email>akrahn@julian.uwo.ca</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:PACE.PACE1258.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received September 11, 2000; revised November 17, 2000; accepted November 30, 2000.</unparsedEditorialHistory><titleGroup><title type="main">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>ANDREW D.</givenNames><familyName>KRAHN</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>GEORGE J.</givenNames><familyName>KLEIN</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>RAYMOND</givenNames><familyName>YEE</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="CA"><unparsedAffiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">dofetilide</keyword><keyword xml:id="k2">supraventricular tachycardia</keyword><keyword xml:id="k3">atrial fibrillation</keyword><keyword xml:id="k4">wolff‐parkinson‐white syndrome</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p> <b>KRAHN, A.D., <sc>et al.</sc>: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome.</b> Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (<span type="mathematics">P = 0.046</span>). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</p><!-- (PACE 2001; 24:1258–1260)
</abstractGroup></contentMeta><noteGroup><note xml:id="n-fnt-1" numbered="no"><p>Supported by a grant from Pfizer Inc., New York, NY.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title></titleInfo><name type="personal"><namePart type="given">ANDREW D.</namePart><namePart type="family">KRAHN</namePart><affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GEORGE J.</namePart><namePart type="family">KLEIN</namePart><affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RAYMOND</namePart><namePart type="family">YEE</namePart><affiliation>Division of Cardiology, University of Western Ontario, London, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Futura Publishing, Inc.</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2001-08</dateIssued><edition>Received September 11, 2000; revised November 17, 2000; accepted November 30, 2000.</edition><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</abstract><subject lang="en"><genre>keywords</genre><topic>dofetilide</topic><topic>supraventricular tachycardia</topic><topic>atrial fibrillation</topic><topic>wolff‐parkinson‐white syndrome</topic></subject><relatedItem type="host"><titleInfo><title>Pacing and Clinical Electrophysiology</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">0147-8389</identifier><identifier type="eISSN">1540-8159</identifier><identifier type="DOI">10.1111/(ISSN)1540-8159</identifier><identifier type="PublisherID">PACE</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>8</number></detail><extent unit="pages"><start>1258</start><end>1260</end><total>3</total></extent></part></relatedItem><identifier type="istex">118ADF7F2B55924522341A65CD078ED7E7AA300A</identifier><identifier type="DOI">10.1046/j.1460-9592.2001.01258.x</identifier><identifier type="ArticleID">PACE1258</identifier><accessCondition type="use and reproduction" contentType="copyright">© Futura Publishing Company, Inc. 2001</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Futura Publishing, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000137 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000137 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A
|texte= A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome
}}
| This area was generated with Dilib version V0.6.29. |  |